Digital repository of Slovenian research organisations

Search the repository
A+ | A- | Help | SLO | ENG

Query: search in
search in
search in
search in

Options:
  Reset


Query: "author" (��ist Andrej) .

21 - 30 / 430
First pagePrevious page12345678910Next pageLast page
21.
Catalytic wet torrefaction of biomass waste into bio-ethanol, levulinic acid, and high quality solid fuel
Andrii Kostyniuk, Blaž Likozar, 2024, original scientific article

Published in DiRROS: 07.03.2024; Views: 100; Downloads: 53
.pdf Full text (5,08 MB)
This document has many files! More...

22.
23.
Cardiac tamponade as the initial manifestation of pulmonary adenocarcinoma : prikaz primera in pregled literature
Mitja Letonja, Andrej Debeljak, 2007, professional article

Abstract: Background. Neoplastic pericarditis can be presented as acute pericarditis, pericardial effusion, effusive-constrictive pericarditis or cardiac tamponade.For the majority of patients, a clinical manifestation of neoplasticpericarditis is absent or remains unrecognised during their life. Case report. A 69-year-old non-smoking woman with acute dyspnoea, tachycardia,jugular venous distension, hepatomegaly and right side pleural effusion was presented in the emergency department. The roentgen picture of the chest confirmed pleural effusion and revealed enlarged heart. An emergencyechocardiogram established the diagnosis of cardiac tamponade. The patient improved immediately after the therapeutic pericardiocentesis. Cytology of pericardial fluid confirmed malignant glandular cells, consistent with metastatic adenocarcinoma. A computed chest tomography showed a right side pleural effusion and a solitary round lesion in the right lower lobe of the lung. Bronchoscopy with fundoscopic lung biopsy and brushing revealed adenocarcinoma. Conclusions. Cardiac tamponade as the initial manifestation ofmalignancy is rare and rare is also malignant pericardial effusion due the adenocarcinoma of the lung in a non-smoking woman. The presented patient had one of the longest survival reported in literature despite a limited life expectancy regardless of the treatment in the patient presented with neoplastic pericarditis.
Published in DiRROS: 22.02.2024; Views: 222; Downloads: 33
.pdf Full text (117,08 KB)

24.
In vivo dosimetry with diodes in rectal cancer patients
Andrej Strojnik, 2007, original scientific article

Published in DiRROS: 20.02.2024; Views: 99; Downloads: 23
.pdf Full text (186,07 KB)

25.
Surgical treatment of malignant pleural mesothelioma
Janez Eržen, Stanko Vidmar, Mihael Sok, Andrej Debeljak, Peter Kecelj, Viljem Kovač, Marjeta Stanovnik, Tomaž Rott, Izidor Kern, 2005, original scientific article

Abstract: Background. The aim of the study was to identify perioperative morbidity and mortality, the category and mode of adjuvant treatment, local recurrence and survival in patients treated by extrapleural pneumonectony (EPP) for malignantpleural mesothelioma (NLPM). Methods. From 2000 to 2003, 18 patients with MPM were referred to the Department of Thoracic Surgery in Ljubljana, and17 of them were operated on. Two patients underwent explorative thoracotomy, and 15 patients were evaluated. Five female and nine male patients (aged 52-68 years) were treated by EPP and one male patient by pleurectomy. Eight patients received both adjuvant chemotherapy (ChT) and radiotherapy (RT), with cisplatin 100 mg/m2 + mitomycin C 6-10 mg/m2 gemcitabine 1000 mg/m2 and external beam radiation with 24 Gy - 58 Gy respectively, three patients received no adjuvant therapy, three patients weretreated by adjuvant ChT, two of them were given cisplatin 100 mg/m2 + mitomycin C 6-10 mg/m2, and one patient cisplatin 100 mg/m2 on the first day and gemcitabine 250 mg/rn2 in prolonged 6 hours infusion on the first and on the eighth day. One patient was treated only by adjuvant RT. Results. There were no perioperative deaths and the postoperative morbidity was 42%. Of the 15 evaluable patients, and in the median follow up of 40 months (28-64), we noticed nine (60.0%) recurrences, seven local and two abdominal. Eight (53.3%)patients died, all because of the local progress of disease. (Abstract truncated at 2000 characters)
Published in DiRROS: 14.02.2024; Views: 146; Downloads: 36
.pdf Full text (82,10 KB)

26.
Characterization of lung cancer patients, their actual treatment and survival : experience of Slovenia
Lučka Debevec, Andrej Debeljak, Janez Eržen, Viljem Kovač, Izidor Kern, 2005, original scientific article

Abstract: Background. The aim of the study was to establish characteristics of lung cancer patients diagnosed at the University Clinic of Respiratory and AllergicDiseases Golnik in 1996, their selected and realized therapy, and survival. Methods. The retrospective study comprises 345 patients aged from 37to 90 years (mean 65), 285 males and 60 females. Performance status (Karnofsky): > 80 in 171 patients, 60-80 in 130 and < 60 in 44 patients. Mirroscopically confirmed tumour in 97%: by bronchoscopy 281, transthoracic needle biopsy 23, peripheral lymph nodes biopsy 12, sputum cytology 7, pleural(effusion) cytology 4, distant metastases biopsy 2, mediastinoscopy 1, autopsy 4 patients. Histology and/or cytology: squamous 131, adenocarcinoma 86, large cell 63, small cell 51, non-small cell 1, unclassified 2. Clinical staging of non-small cell lung cancer (NSCLC): stage I 63, stage ll 32, stage IIIA 48, stage IIIB 59, stage IV 77, undeterminable 2 patients. Staging in small cell lung cancer (SCLC): limited disease 24, extended disease 27 patients. Results. The selected primary oncological therapy was changed in 11%. Realized primary therapy: radiotherapy 102 (30%), surgery 77 (23%), chemotherapy 47 (14%), supportive treatment 111 (33%). In resected patients staging was correct in 46%, underestimated in 44%, overestimated in 10%. The overall five-year survival was 7.8% (median 6.2 months) and the five year survival of resected patients was 41.9% (median 33 months). The median survival of irradiated patients was 5.7 months, of supportively treated patients 2.5 months. The survival was significantly different according to theperformance status and stage. (Abstract truncated at 2000 characters)
Published in DiRROS: 14.02.2024; Views: 129; Downloads: 30
.pdf Full text (88,13 KB)

27.
Breast cancer and breast health awareness as an evolving health promotion concept
Andrej Plesničar, Viljem Kovač, Božo Kralj, 2004, original scientific article

Abstract: Background. Breast cancer is the most frequent malignant disease in the majority of developed countries. In the last few years the introduction of mammography screening programmes has resulted in an improved survival of breast cancer patients. However, the incidence of the disease in these countries is still on the increase. Present focus on secondary breast cancer prevention activities, consisting of early detection and treatment, cannot ensure a decrease of breast cancer incidence. Improved breast health awarenesscould therefore represent a part of specific health promotion activities aimed at decreasing the incidence of breast cancer. Conclusions. Indeveloped countries breast cancer is a significant health care issue. Secondary breast cancer prevention activities should therefore be complementedby specific health promotion activities in order to reduce its incidence in the future. Primary breast cancer prevention would include healthpromotion activities aimed at enhancement of the individual as well as collective breast health awareness. Properly enlightened members of the influential population groups could attain appropriate changes in the fields of legislation, taxation, customs and commercial regulations that would enablewomen to control their own breast health.
Published in DiRROS: 07.02.2024; Views: 171; Downloads: 35
.pdf Full text (84,20 KB)

28.
29.
Detection of apoptotic cells in tumour paraffin sections
Jože Pižem, Andrej Cör, 2003, professional article

Abstract: Apoptosis is a distinct form of cell death characterised by specific morphological features and regulated by complex molecular mechanisms. Its deregulation is fundamental for tumour growth and progression and, moreover, anticancer therapies suppress tumour growth mainly by induction of apoptosis. Since the extent of apoptosis in a tumour may have prognostic as well as therapeutic implications, much effort has been invested in developing specificmethods that can be routinely used to detect apoptotic cells in archival formalin fixed paraffin-embedded tissue. Complex molecular pathways are involved in the regulation of apoptosis. Pro-apoptotic signals trigger activation of caspases that specifically cleave target proteins. Cleavage of proteins (caspase substrates) is responsible for morphological changes of apoptotic cells and DNA fragmentation. In the last decade, detection of apoptotic cells in formalin fixed tumour tissue sections has been based mainlyon morphology and characteristic DNA fragmentation. Recently, specific antibodies to activated caspases and cleaved target proteins (including cytokeratin 18, actin and PARP) have been produced that enable accurate detection of apoptosis in paraffin sections.
Published in DiRROS: 06.02.2024; Views: 138; Downloads: 34
.pdf Full text (170,01 KB)

30.
Survivin - an inhibitor of apoptosis and a new therapeutic target in cancer
Jože Pižem, Andrej Cör, 2003, professional article

Abstract: Survivin is a unique member of the inhibitor of apoptosis (IAP) protein family. It inhibits apoptosis by interfering with post-mitochondrial events during apoptosis, thus blocking activation of caspases. The expression of survivin is among the most tumour specific of all human genes. It is overexpressed in most human cancers but is not detected in most normal tissues. Some molecular mechanisms of survivin upregulation in cancer have been elucidated, including loss of the wild-type p53. Tumours that overexpresssurvivin generally bear a worse prognosis and are associated with resistance to therapy. Its differential expression in caneer versus normal tissues makes survivin detection a useful tool in cancer diagnostics and a promising therapeutic target. Survivin targeting has resulted in increased spontaneous and induced apoptosis and inhibition of tumourgrowth. Some anticaneer drugs currently introduced into clinical practice might well act byinactivaring survivin.
Published in DiRROS: 06.02.2024; Views: 157; Downloads: 32
.pdf Full text (185,35 KB)

Search done in 2 sec.
Back to top